Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Robert Grubbs
AddedMar 31, 2024
UpdatedMay 31, 2026
Robert Grubbs

Robert Grubbs

Co-Founder, Cypris Materials

Crunchbase

Robert Grubbs's Career

Cypris Materials
Cypris Materials

Berkeley, CA, US

Co-Founder
Calando Pharmaceuticals
Calando Pharmaceuticals

Pasadena, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Robert Grubbs's Career

Cypris Materials
Cypris Materials
Pre-Seed$1.2M92019Berkeley, CA, US
Co-Founder

Leadership at Cypris Materials

Raymond WeitekampRaymond WeitekampCo-Founder
Matthew RyanMatthew RyanCo-Founder
Garret MiyakeGarret MiyakeCo-Founder
Ryan PearsonRyan PearsonCo-Founder
Calando Pharmaceuticals
Calando Pharmaceuticals
Acquired$11M02005Pasadena, CA, US
Co-Founder

Leadership at Calando Pharmaceuticals

Mark E. DavisMark E. DavisCo-Founder
Christopher AnzaloneChristopher AnzaloneBoard Member
R. Bruce StewartR. Bruce StewartBoard Member
Dr Mostafa AnalouiDr Mostafa AnalouiBoard Member

Similar to Calando Pharmaceuticals

NantBioNantBioCulver City, CA, USPharmaceuticalsNantBioCulver City, CA, US

NantBioscience: LA-based developer of targeted pharmaceuticals for cancer treatment.

Late Stage Private · $180.1M75
Camino PharmaCamino PharmaSan Diego, CA, USCancer Treatment, Drug Developmentest. 2014Camino PharmaSan Diego, CA, US · est. 2014

Camino Pharma: A tech startup pioneering first-in-class cancer and CNS disorder therapies.

Seed · $13.7M3
LocanabioLocanabioSan Diego, CA, USGene Therapiesest. 2016LocanabioSan Diego, CA, US · est. 2016

Locana: Pioneering RNA-targeting gene therapies for devastating diseases.

Series B · $155.6M175
Nextrna TherapeuticsNextrna TherapeuticsBoston, MA, USTherapeuticsest. 2020Nextrna TherapeuticsBoston, MA, US · est. 2020

NextRNA Therapeutics: Innovating RNA-directed therapeutics to combat disease-causing ncRNAs.

Series A · $56.1M33

Robert Grubbs's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Robert Grubbs

Robert ShapiroRobert ShapiroBoard Member · Sandbox IndustriesDaniel G. NoceraDaniel G. NoceraCo-Founder · Kula BioStephen BenkovicStephen BenkovicCo-Founder · BoragenFrances ArnoldFrances ArnoldBoard Member · AlphabetSamir MitragotriSamir MitragotriFounder · i2o TherapeuticsBrian StoltzBrian StoltzCo-Founder · 1200 Pharma